



Ramon L. Varcoe MBBS, MS, FRACS, PhD, MMed (ClinEpi)

Prince of Wales Hospital and University of New South Wales

Sydney, Australia



Disclosures



Consultant to

- Surmodics
- Medtronic
- Abbott Vascular
- BD Bard
- Intervene
- Philips Healthcare
- Nectero Medical
- Alucent Biomedical
- W.L. Gore


Shareholder

- EBR Systems
- Provisio Medical, inc

Sirolimus DCB Requirements and Challenges

ADVANTAGES OF SIROLIMUS

- Potent anti-inflammatory and antiproliferative effects
- Cytostatic rather than cytotoxic mechanism¹
- Proven history of safety and efficacy^{2,3}



1. Mori, 2021 2. Scheinert, 1-year Results from ACHILLES Trial, 2012 3. Zeller, LINC, 2011 Yukon BTK study 4. Finn, NCVH, 2022



CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.




Sirolimus DCB Requirements and Challenges

SIROLIMUS DELIVERY REQUIREMENTS

- High initial transfer to form sufficient drug depot
- Continuous release of **bioavailable drug** at therapeutic levels
- Drug presence for **90 days** to inhibit restenotic response⁴





© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device Limited by Federal (or United States) law to investigational use.





Hydrophilic shaft coating Surmodics SERENE[™] hydrophilic

coating

Uniform Sirolimus drug coat

Microcrystalline sirolimus + proprietary excipient 360° uniform coating coverage





Sundance[™] DCB Next-gen Coating Technology

• Excellent coating durability to maximize drug transfer

- Enhanced sirolimus delivery and sustained therapeutic levels in artery
- Best-in-class hydrophilic coating and enhanced trackability



CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates.




SURMODICS


Hydrophilic shaft coating Surmodics SERENE[™] hydrophilic

coating

Uniform Sirolimus drug coat

Microcrystalline sirolimus + proprietary excipient 360° uniform coating coverage





Sundance[™] DCB Next-gen Coating Technology

• Excellent coating durability to maximize drug transfer

- Enhanced sirolimus delivery and sustained therapeutic levels in artery
- Best-in-class hydrophilic coating and enhanced trackability



CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates.




SURMODICS

Hydrophilic shaft coating Surmodics SERENE[™] hydrophilic coating

Uniform Sirolimus drug coat

Microcrystalline sirolimus + proprietary excipient 360° uniform coating coverage



Surmodics .014" PTA platform 2 - 4 mm diameter 20 - 220 mm lengths

Sundance[™] DCB Next-gen Coating Technology

- Excellent coating durability to maximize drug transfer
- Enhanced sirolimus delivery and sustained therapeutic levels in artery
- Best-in-class hydrophilic coating and enhanced trackability



CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates.



SURMODICS

Hydrophilic shaft coating Surmodics SERENE[™] hydrophilic coating

Uniform Sirolimus drug coat

Microcrystalline sirolimus + proprietary excipient 360° uniform coating coverage



Surmodics .014" PTA platform 2 - 4 mm diameter 20 - 220 mm lengths

Sundance[™] DCB Next-gen Coating Technology

- Excellent coating durability to maximize drug transfer
- Enhanced sirolimus delivery and sustained therapeutic levels in artery
- Best-in-class hydrophilic coating and enhanced trackability



CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates.




PSURMODICS

Sundance[™] DCB Microcrystalline Sirolimus Technology

have the second of the second states of the second states of the






Microcrystalline Technology Advantages

- Enhanced purity and stability
- Uniform coating and drug dose density
- Greater transfer and sustained levels in arterial tissue

MagicTouch™ DCB Non-uniform Drug Form








© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates.

Based on bench testing by Surmodics, Inc. Data on file. Bench test results may not necessarily be indicative of clinical performar

Tissue Drug Levels






SURMODICS


CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

© 2022 Surmodics, Inc. All rights reserved.

SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates. Surmodics data from porcine peripheral model testing. Results may not be indicative of clinical performance.

Preclinical Histopathology Demonstrates Biological Effect of Sirolimus









© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates. Surmodics data from porcine peripheral model testing. Results may not be indicative of clinical performance.

Selution data: A. Finn. TCT. 2021



Sundance[®] Drug-Coated Balloon Trial

An Evaluation of the Sundance[™] DCB Belowthe-knee





© 2022 Surmodics, Inc. All rights reserved. CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

PROTOCOL SYNOPSIS

Investigational Device	Surmodics SUNDANCE™ Sirolimus Drug-Coated Balloon (Sundance™ DCB)	
Objectives	To evaluate the safety and performance of Sundance™ DCB in subjects with occlusive disease of the infrapopliteal arteries.	
Study Design	Prospective, multi-center, single-arm, feasibility study. To evaluate the safety and performance of the Sundance [™] DCB in subjects with occlusive disease of the infra-popliteal arteries. Subjects will be followed for 36 months following the index procedure.	
Subject Populations	Subjects with stenotic or occluded lesions of the infrapopliteal arteries with a reference vessel diameter (RVD) of 2 mm to 4 mm and a total lesion length of <230 mm.	
Subjects and Sites	35 subjects at 8 sites in Australia, New Zealand and/or Europe.	

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.



KEY INCLUSION/EXCLUSION CRITERIA

- Rutherford 4 or 5 (RC 3 are included but capped at 20% of cohort)
- De Novo or restenotic (non-stented) lesions
- ≥70% stenosis by visual estimate
- Up to two distinct lesions in the same or different BTK arteries
- Must have good or successfully treated inflow and an unimpaired outflow artery in continuity to the ankle/foot



ANALYSIS POPULATIONS MITT and PP

	Modified Intent to Treat (MITT)	Per-Protocol Analysis Population (PP)
DEFINITION	The MITT population consists of all ITT subjects who met all pre-procedure angiographic eligibility criteria, and in whom treatment with the Sundance™ DCB was attempted.	 The PP population is a subset of the MITT population who meet the following oritorie. The subject received treatment with the Sundance[™] DCB (n=0) No major deviations from the protocol eligibility criteria (n=3) The subject had a 6-month primary efficacy assessment (angio) (n=7)
TOTAL SUBJECTS	35 Subjects	25 Subjects
TOTAL LESIONS	43 Lesions	33 Lesions
Sites	8 Sites	8 Sites
2022 Surmodics, Inc. All rights reserved. AUTION Sundance™ Drug-Coated Balloon is an	SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trac	lemarks of Surmodics, Inc. and/or its affiliates. Sundance are SURMODICS

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.



BASELINE DEMOGRAPHICS

Characteristic	MITT (N=35)	PP (N=25)
Age (years) Mean ± SD	76.8±10.0	75.4 ± 9.9
Gender (Male)	22/35 (62.9%)	16/25 (64.0%)
Smoker (Current and Former)	14/35 (40.0%)	10/25 (40.0%)
Diabetes (Type 2)	21/35 (60.0%)	15/25 (60.0%)
Hypertension	32/35 (91.4%)	24/25 (96.0%)
Hypercholesterolemia	22/35 (62.9%)	16/25 (64.0%)
Rutherford Clinical Classification		
Category 3	4/35 (11.4%)	3/25 (12.0%)
Category 4	8/35 (22.9%)	7/25 (28.0%)
Category 5	23/35 (65.7%)	15/25 (60.0%)





© 2022 Surmodics, Inc. All rights reserved. CAUTION Sundance[™] Drug-Coated Balloon is an investigational device.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

BASELINE DEMOGRAPHICS

Characteristic	MITT (N=35)	PP (N=25)
Age (years) Mean ± SD	76.8±10.0	75.4 ± 9.9
Gender (Male)	22/35 (62.9%)	16/25 (64.0%)
Smoker (Current and Former)	14/35 (40.0%)	<mark>10/25 (40.0%)</mark>
Diabetes (Type 2)	21/35 (60.0%)	<mark>15/25 (60.0%)</mark>
Hypertension	32/35 (91.4%)	24/25 (96.0%)
Hypercholesterolemia	22/35 (62.9%)	16/25 (64.0%)
Rutherford Clinical Classification		
Category 3	4/35 (11.4%)	3/25 (12.0%)
Category 4	8/35 (22.9%)	7/25 (28.0%)
Category 5	23/35 (65.7%)	15/25 (60.0%)





© 2022 Surmodics, Inc. All rights reserved. CAUTION Sundance[™] Drug-Coated Balloon is an investigational device.

BASELINE DEMOGRAPHICS

Characteristic	MITT (N=35)	PP (N=25)
Age (years) Mean ± SD	76.8±10.0	75.4 ± 9.9
Gender (Male)	22/35 (62.9%)	16/25 (64.0%)
Smoker (Current and Former)	14/35 (40.0%)	10/25 (40.0%)
Diabetes (Type 2)	21/35 (60.0%)	15/25 (60.0%)
Hypertension	32/35 (91.4%)	24/25 (96.0%)
Hypercholesterolemia	22/35 (62.9%)	16/25 (64.0%)
Rutherford Clinical Classification		
Category 3	4/35 (11.4%)	3/25 (12.0%)
Category 4	8/35 (22.9%)	<mark>7/25 (28.0%)</mark>
Category 5	23/35 (65.7%)	<mark>15/25 (60.0%)</mark>





© 2022 Surmodics, Inc. All rights reserved. CAUTION Sundance[™] Drug-Coated Balloon is an investigational device.

LESION & PROCEDURAL CHARACTERISTICS

Characteristic ¹	MITT (N=35)	PP (N=25)
Lesion Length (mm)	83.8±76.6 (43)	72.4 ± 66.6(33)
Diameter Stenosis (%)	82.8±13.9 (43)	81.8 ±13.9 (33)
Calcification		
None/Mild	11/43 (25.6%)	6/33 (18.2%)
Moderate	26/43 (60.5%)	24/33 (72.7%)
Severe	6/43 (14.0%)	3/33 (9.1%)
Total Occlusion	14/43 (25.6%)	10/33 (30.3%)
Procedure Time (min) ²	62.5±21.5 (35)	60.5±17.4 (25)
MLD after DCB (mm)	2.4±0.7(43)	2.5±0.6 (33)
Diameter Stenosis after DCB (%)	22.3±16.5(43)	20.6±11.8 (33)
Post Dilatation Performed ³	7/35 (20.0%)	5/25 (20%)

¹ Core Lab reported data unless noted otherwise, N reflects per lesion data ² Site reported data, N reflects per subject data ³ N reflects total number of subjects



LESION & PROCEDURAL CHARACTERISTICS

Characteristic ¹	MITT (N=35)	PP (N=25)
Lesion Length (mm)	83.8±76.6 (43)	72.4 ± 66.6(33)
Diameter Stenosis (%)	82.8±13.9 (43)	81.8 ±13.9 (33)
Calcification		
None/Mild	11/43 (25.6%)	6/33 (18.2%)
Moderate	26/43 (60.5%)	<mark>24/33 (72.7%)</mark>
Severe	6/43 (14.0%)	<mark>3/33 (9.1%)</mark>
Total Occlusion	14/43 (25.6%)	10/33 (30.3%)
Procedure Time (min) ²	62.5±21.5 (35)	60.5±17.4 (25)
MLD after DCB (mm)	2.4±0.7(43)	2.5±0.6 (33)
Diameter Stenosis after DCB (%)	22.3±16.5(43)	20.6±11.8 (33)
Post Dilatation Performed ³	7/35 (20.0%)	5/25 (20%)

¹ Core Lab reported data unless noted otherwise, N reflects per lesion data ² Site reported data, N reflects per subject data ³ N reflects total number of subjects





LESION & PROCEDURAL CHARACTERISTICS

Characteristic ¹	MITT (N=35)	PP (N=25)
Lesion Length (mm)	83.8±76.6 (43)	72.4 ± 66.6(33)
Diameter Stenosis (%)	82.8±13.9 (43)	81.8 ±13.9 (33)
Calcification		
None/Mild	11/43 (25.6%)	6/33 (18.2%)
Moderate	26/43 (60.5%)	24/33 (72.7%)
Severe	6/43 (14.0%)	3/33 (9.1%)
Total Occlusion	14/43 (25.6%)	<mark>10/33 (30.3%)</mark>
Procedure Time (min) ²	62.5±21.5 (35)	60.5±17.4 (25)
MLD after DCB (mm)	2.4±0.7(43)	2.5±0.6 (33)
Diameter Stenosis after DCB (%)	22.3±16.5(43)	20.6±11.8 (33)
Post Dilatation Performed ³	7/35 (20.0%)	5/25 (20%)

¹ Core Lab reported data unless noted otherwise, N reflects per lesion data ² Site reported data, N reflects per subject data ³ N reflects total number of subjects

evice. SURMODICS, SE

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

© 2022 Surmodics, Inc. All rights reserved.







PRIMARY ENDPOINTS

Primary <u>Safety</u> Endpoint Composite freedom from Major Adverse Limb Event (MALE) + Perioperative death (POD) at 30 days.

Primary <u>Efficacy</u> Endpoint Late Lumen Loss (LLL) at 6 Months assessed by quantitative vascular angiography (QVA).



 $\mathsf{CAUTION}\xspace$ Sundance $^{\texttt{w}}$ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.





PRIMARY <u>SAFETY</u> ENDPOINT

Primary Safety Endpoint	MITT Population (subjects)	PP Population (Subjects)
Composite Primary Safety Endpoint	97.1% (33/34)	100.0% (25/25)
Freedom from MALE ¹	97.1% (33/34)	100.0% (25/25)
Major Amputation	0.0% (0/34)	0.0% (0/25)
Major Re-intervention	2.9% (1/34)	0.0% (0/25)
Freedom from POD ²	100.0% (34/34)	100.0% (25/25)

¹MALE: Major Adverse Limb Event - a composite of either major amputation or major surgical re-intervention through 30 days of the index procedure ²POD: Perioperative death at 30 days

N = number of subjects with data available at timepoint



© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

MAJOR ADVERSE EVENTS

Key Secondary Endpoints	MITT Population	PP Population	MITT Population	PP Population
	6 Month		12 Month	
Major Adverse Event ¹	12.9% (4/31)	8.0% (2/25)	15.2% (5/33)	8.0% (2/25)
Rate of All-Cause Death	0.0% (0/31)	0.0% (0/25)	3.0% (1/33)	0.0% (0/25)
Target Limb Amputation	0.0% (0/31)	0.0% (0/25)	0.0% (0/33)	0.0% (0/25)
CD-TLR ²	12.9% (4/31)	8.0% (2/25)	12.1% (4/33)	8.0% (2/25)

¹ Major Adverse Event: A composite rate of all-cause death, target limb major amputation and CD TLR ² Clinically driven Target Lesion Revascularizations (CD TLR): Any TLR of the target lesion associated with deterioration of Rutherford Clinical Classification and/or increase in size of pre-existing wounds and/or occurrence of new wound(s), and lesion restenosis >50% determined by angiography.




© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[®] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

PRIMARY <u>EFFICACY</u> ENDPOINT

Primary Efficacy Endpoint (per lesion)	MITT Population (43 lesions)	PP Population (33 lesions)
N Ý	Value (mm)	Value (mm)
MLD After Procedure	2.5±0.64 (43)	2.6±0.48 (33)
MLD at 6 mth Follow-up	1.5±1.01 (35)	1.5±0.97(33)
Late Lumen Loss ¹	1.0±0.79 (35)	1.0±0.79 (33)



Sundance DRUG-COATED BALLOOI

¹ The primary efficacy endpoint is Late Lumen Loss (LLL) at 6 Months assessed by quantitative vascular angiography (QVA).


© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device.



PRIMARY <u>EFFICACY</u> ENDPOINT

Primary Efficacy Endpoint (per lesion)	MITT Population (43 lesions)	PP Population (33 lesions)
N Ý	Value (mm)	Value (mm)
MLD After Procedure	<mark>2.5±0.64 (43)</mark>	<mark>2.6±0.48 (33)</mark>
MLD at 6 mth Follow-up	1.5±1.01 (35)	1.5±0.97(33)
Late Lumen Loss ¹	1.0±0.79 (35)	1.0±0.79 (33)




¹ The primary efficacy endpoint is Late Lumen Loss (LLL) at 6 Months assessed by quantitative vascular angiography (QVA).

© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

COMPARISON OF LUMINAL GAIN





© 2022 Surmodics, Inc. All rights reserved.


CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use. SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates.

Third Party trademarks are the property of their respective owners

TARGET LESION PRIMARY PATENCY (per lesion)

Primary Patency 1	MITT Population (43 Lesions)	PP Population (33 Lesions)
6-Months	80.0% (24/30)	88.5% (23/26)
12-Months	71.4% (20/28)	80.0% (20/25)

¹ Patency is defined as freedom from target vessel occlusion as determined by DUS and CD-TLR. Clinically driven Target Lesion Revascularizations (CD TLR): Any TLR of the target lesion associated with deterioration of Rutherford Clinical Classification and/or increase in size of pre-existing wounds and/or occurrence of new wound(s), and lesion restenosis >50% determined by angiography.








© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

ANGIOGRAPHIC BINARY RESTENOSIS (6mo)



© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance $^{\rm w}$ Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

6-9 month follow-up; Sundance™ DCB data PP population Ranger™ DCB reported composite endpoint CD-TLR + binary restenosis; Sundance™ DCB calculated via this endpoint 36.4% (no change from graph)

Third party trademarks are the property of their respective owners SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates







Rutherford-Becker Classification

MITT Population

PP Population





Significant clinical improvement: 76% of PP subjects demonstrated improvement at 12 months

Durable clinical outcomes: Improvement in Rutherford Clinical Classification increased between the 1-month, 6month, and 12month endpoints






© 2022 Surmodics, Inc. All rights reserved.

CAUTION Sundance[™] Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.

PATIENT REPORTED OUTCOME MEASURES

Baseline ■1M ■6M ■12m 80.0 Values at each Timepoint 70.0 60.0 50.0 40.0 30.0 20.0 10.0 0.0 EQ VAS WIQ WD Vascu QOL Baseline 63.3 36.8 3.9 **1** M 64.8 41.6 4.7 6 M 67.5 53.3 5.1 12 m 67.4 54.5 5.4

MITT Population



PP Population

© 2022 Surmodics, Inc. All rights reserved.

 $\label{eq:CAUTION Sundance^w} Drug-Coated Balloon is an investigational device. Limited by Federal (or United States) law to investigational use.$

SURMODICS, SERENE, SUNDANCE, and SUNDANCE and SURMODICS logos are trademarks of Surmodics, Inc. and/or its affiliates.



CONCLUSION

- The Sundance[™] DCB was evaluated in a challenging, real-world, (predominantly) CLI population with a high proportion of diabetes and moderate-severe calcification
- Preclinical studies demonstrate sustained levels of sirolimus in arterial tissue and robust biological effects
- SWING clinical results are promising with an excellent safety profile and 12-month primary patency of 80% (per protocol)
- This novel device has great promise and warrants evaluation in a largescale pivotal trial







Ramon L. Varcoe MBBS, MS, FRACS, PhD, MMed (ClinEpi)

Prince of Wales Hospital and University of New South Wales

Sydney, Australia